Ablaze Pharmaceuticals
China
- Shanghai
- 29/11/2021
- Series A
- $75,000,000
Ablaze Pharma is a clinical stage Biopharmaceutical Company which is focused on the developing innovative Targeted Radiotherapy (TRT) to benefit cancer patients in China.
- Industry Pharmaceutical Manufacturing
- Website http://www.ablazepharma.com/
- LinkedIn https://www.linkedin.com/company/ablaze-pharmaceuticals-shanghai-co-ltd/
Related People
Tiecheng Alex QiaoFounder
United States -
San Diego, California,
Serial Entrepreneur experienced in high tech start ups. Twenty years of extensive knowledge in managing complex technologies and technology product development. A proven track record of conceiving and growing companies from concept to successful market entry, developing new product concepts, sourcing and managing co-development activities both in US and in China. Demonstrated success in building and leading multi-functional teams, strategic planning, and decision making. Also an inventor with 25 issued US patents and experience in developing and managing Intellectual Property.
Specialties: Conceiving and developing high tech business from concept to commercial success. Team building in high tech start up companies. Integrated product development and commercialization.
Healthfab | $2,100,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)